Human Milk Oligosaccharides (HMO) Market Share, Size, Trends, Industry Analysis Report, By Type (2’FL, 3’FL, 3’SL, 6’SL); By Application; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032

Human Milk Oligosaccharides (HMO) Market Share, Size, Trends, Industry Analysis Report, By Type (2’FL, 3’FL, 3’SL, 6’SL); By Application; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032

The global human milk oligosaccharides (HMO) market size is expected to reach USD 1,799.96 million by 2032, according to a new study by Polaris Market Research. The report “Human Milk Oligosaccharides (HMO) Market Share, Size, Trends, Industry Analysis Report, By Type (2’FL, 3’FL, 3’SL, 6’SL); By Application; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Human Milk Oligosaccharides (HMOs) are complex carbohydrates or sugars naturally found in human breast milk. HMOs are unique to human milk and are not present in significant amounts in other mammalian milk, including cow's milk.

HMOs serve as a source of infant nutrition, although the baby does not directly digest them. Instead, they act as prebiotics, which means they serve as food for beneficial bacteria in the infant's gut. The gut microbiota is crucial in immune system development, digestion, and overall health. HMOs selectively promote the growth of specific beneficial bacteria, such as Bifidobacteria, while inhibiting the growth of harmful pathogens.

Human Milk Oligosaccharides (HMOs) are essential constituents of human breast milk and are available in various concentrations and compositions. The unique nature of HMOs requires specific regulatory approvals for their use. In the United States, oligosaccharides are authorized to be incorporated into food products rather than categorized as dietary supplements and are subject to the Generally Recognized as Safe (GRAS) regulations.

For instance, the GRAS-approved HMO product line is CARE4U, developed by DuPont, which is utilized in infant formula and toddler foods. This approval ensures its safety for consumption. Furthermore, the growing demand for HMOs has led to a novel food safety assessment to seek support from the European Commission for their usage.

The global adoption of Human Milk Oligosaccharides (HMOs) has increased. According to a World Economic Forum article published in January 2022, the number of births in Japan decreased by 2.8% in 2020 compared to the previous year, reaching its lowest point since 1899.

The increasing demand for HMOs can be attributed to lifestyle improvements and a growing focus on health and wellness. HMOs are utilized in functional food and beverage products and food supplements to address disorders and mitigate high-risk health conditions. This factor has significantly contributed to the growth of the global HMO industry. However, the high costs associated with HMO products are expected to pose a major challenge to market growth during the forecast period.

The COVID-19 pandemic has had a significant impact on the HMO industry. During the initial phase of the pandemic, there was a surge in demand for HMOs as consumers engaged in panic buying for at-home consumption. It resulted in increased sales of HMOs, considered immune-boosting products.

Human Milk Oligosaccharides (HMO) Market Report Highlights

In 2022, the infant formula segment accounted for the largest market share due to the increasing demand for HMOs in infant formula design. HMOs offer beneficial properties like prebiotic effects, infection prevention, memory enhancement, gut health maintenance, and brain development. These factors drive the demand for HMOs in infant formulas.

In 2022, the drug store or pharmacy segment held the highest market share in the Human Milk Oligosaccharides market and is projected to continue growing. It is primarily due to the segment's focus on attracting and retaining customers amidst rising competition from mail-order retailers and supercenters.

The Asia Pacific region expected to witness significant growth in the Human Milk Oligosaccharides (HMO) market due to growing awareness of the benefits of HMOs in infant nutrition and overall health in the region. As consumers become more health-conscious and seek high-quality nutrition options for their infants, the demand for HMOs is expected to rise.

The global Human Milk Oligosaccharides industry players with a global presence including Elicityl S.A., Abbott Laboratories, Biosynth Carbosynth, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Glycosyn, BASF S.E., Glycom A/S, Nestle Health Science, Neolacta Lifesciences Pvt. Ltd, Royal DSM, Medolac Laboratories, Chr. Hansen Holding A/S, ZuChem, Inbiose NV, and Royal FrieslandCampina N.V.

Polaris Market Research has segmented the human milk oligosaccharides (HMO) market report based on type, application, distribution channel, and region:

Human Milk Oligosaccharides (HMO), Type Outlook (Revenue - USD Million, 2019 - 2032)

2’FL

3’FL

3’SL

6’SL

Human Milk Oligosaccharides (HMO), Application Outlook (Revenue - USD Million, 2019 - 2032)

Infant Formula

Functional Food & Beverage

Food Supplements

Human Milk Oligosaccharides (HMO), Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

Hypermarkets & Supermarkets

Drug Store or Pharmacy

Online Sales Channel

Others

Fogless Mirror, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa